



**American Association of Ophthalmic Oncologists and Pathologists  
Annual Meeting**

Rush University Medical Center  
Department of Ophthalmology  
1725 W. Harrison, Chicago, IL 60612  
**Friday, October 18, 2024**

7:30 AM – 8:00 AM	Registration and Breakfast	
8:00 AM – 8:05 AM	<b>President's Welcome</b>	Matthew Wilson, MD President of AAOOP
<b>8:05 AM – 8:25 AM</b>	<b>Free Papers - Section 1 - Vitreoretinal Lymphoma</b>	<b>Moderators:</b> Maya Eiger-Moscovich, MD Dan Gombos, MD
8:05 AM – 8:15 AM	Factors Associated with Delayed Diagnosis in Patients with Primary Vitreoretinal Lymphoma	Timothy Xu, MD
8:15 AM – 8:25 AM	Seasonal Variation in Vitreoretinal Lymphoma Diagnosis	Maya Eiger-Moscovich, MD
<b>8:25 AM – 9:05 AM</b>	<b>Panel Discussion: Best Diagnostic Techniques for Vitreo- Retinal Lymphoma</b>	<b>Moderators:</b> Maya Eiger-Moscovich, MD Dan Gombos, MD
8:25 AM – 8:32 AM	1) Morphologic Confirmation of Malignancy Is Essential in the Diagnosis of Vitreo-Retinal Lymphoma at Houston-Methodist Hospital	Patricia Chevez-Barríos, MD
8:32 AM – 8:39 AM	2) Preferred Approach for the Diagnosis of Vitreo-Retinal Lymphoma at Washington University in St. Louis: Cytologic Smears, Immunohistochemistry, and Cytokines	George Harocopos, MD
8:39 AM – 8:46 AM	3) Preferred Approach at the Bascom-Palmer Eye Institute	Sander Dubovy, MD
8:46 AM – 8:53 AM	4) Preferred Approach at the University of Michigan	Rajesh Rao, MD
8:53 AM – 9:05 AM	Discussion/Questions for Panel	



<b>9:05 AM – 10:05 AM</b>	<b>Free Papers - Section 2 - Retinoblastoma</b>	<b>Moderators:</b> Basil K. Williams, MD Patricia Chevez-Barrios, MD
9:05 AM – 9:15 AM	Evolving Criteria for Group E Retinoblastoma	Arun Singh, MD
9:15 AM – 9:25 AM	Hybrid Biallelic Inactivating RB Mutations and NMYC Amplification in Unilateral Retinoblastoma	Mariana Moctezuma Davila, MD
9:25 AM – 9:35 AM	Long-Read Sequencing of the RB1 Gene for Rapid Diagnosis of Germline RB1 Variants	Andrew Stacey, MD
9:35 AM – 9:45 AM	Very Late Recurrence of Retinoblastoma Following Primary Treatment with Intra-Arterial Chemotherapy	Dan Gombos, MD
9:45 AM – 9:55 AM	Socioeconomic and Racial Differences in Patients Who Underwent Enucleation for Retinoblastoma: A Clinical-Pathologic Analysis	Ari August, BA
9:55 AM – 10:05 AM	Diffuse Infiltrating Retinoblastoma: A Multicenter, International, Data-Sharing Study	Ankit Tomar, MD
<b>10:05 AM – 10:25 AM</b>	<b>Coffee Break &amp; Posters</b>	
<b>10:25 AM – 10:35 AM</b>	<b>Questions For Poster Presenters</b>	<b>Moderators:</b> Zelia Correa, MD, PhD Paul Bryar, MD
	1) Uveal Melanoma: Am I Cured Yet?	Arun Singh, MD
	2) A Predictive Model for Iris Melanoma	Arun Singh, MD
	3) Leveraging Deep Learning for Functional Analysis of Missense Mutations in Uveal Melanoma with Alphasense	David Gonzales, MD
	4) Lipid Dominant Chorioretinopathy: A Chronic Variant of Toxic Tumor Syndrome	Jose Puthussery, MD
<b>10:35 AM – 12:25 PM</b>	<b>Free Papers - Section 3 - Melanoma</b>	<b>Moderators:</b> Prithvi Mruthyunjaya, MD, MHS Benjamin King, MD Sander Dubovy, MD
10:35 AM – 10:45 AM	Conjunctival Melanoma: Features, Biomarkers, and Outcomes Based on Iris Color in 700 Consecutive Patients	Carol Shields, MD
10:45 AM – 10:55 AM	Primary Acquired Melanosis/Melanoma: Utility of Conjunctival Map Biopsy	Arun Singh, MD
10:55 AM – 11:05 AM	The Living Library for Uveal Melanoma: Multiomics Characterization and Utility in Drug Screening	Lauren Dalvin, MD



11:05 AM – 11:15 AM	Uveal Melanoma in BAP1 Tumor Predisposition Syndrome: Estimation of Risk	R. Chris Bowen, MD, MS
11:15 AM – 11:25 AM	Comparison Of Cytopathological Yield of Fine Needle Aspiration Biopsy of Melanocytic Uveal Tumors Diagnosed Clinically as Uveal Melanoma Using 25g Versus 27g Needles	Gustavo Gameiro, MD
11:25 AM – 11:35 AM	Utility and Safety of a 41g Ultrafine Needle Aspiration Biopsy (U-FNAB) for Small Posterior Uveal Melanoma: A Series of 16 Cases	Deanna Miano, DO, MS
11:35 AM – 11:45 AM	Uveal Melanoma Following Bruton's Tyrosine Inhibitor Use for the Treatment of Hematologic Malignancies	Tara Murty, BS
11:45 AM – 11:55 AM	Diagnostic Challenge of a Large Choroidal Tumor	Benjamin Steren, MD
11:55 AM – 12:05 PM	Stem-Like Signatures and Gene Expression Patterns Reveal Complex Dynamics in Uveal Melanoma	Linda Cernichiaro-Espinosa, MD
12:05 PM – 12:15 PM	Machine Learning Analysis of Uveal Melanoma Imaging	Michael Heiferman, MD
12:15 PM – 12:25 PM	Uveal Melanoma Gene Expression Profile Prediction from Ultra-Widefield Fundus Photographs Using Automated Machine Learning	Jared Sokol, MD, MBA
<b>12:25 PM – 1:40 PM</b>	<b>Lunch/Business Meeting for Members</b>	
<b>1:40 PM – 2:30 PM</b>	<b>Special Panel: The Future of Ophthalmic Pathology: Is It in Jeopardy, and What Can We Do About It?</b>	<b>Moderator:</b> Tatyana Milman, MD
	Presentation of Membership Survey Data	George Harocopos, MD
	Recorded Presentation	Jane Edmond, MD President, AAO
	Panel Discussion	Dan Gombos, MD George Harocopos, MD Matthew Wilson, MD
<b>2:30 PM – 2:50 PM</b>	<b>Free Papers - Section 4 - Cornea/Conjunctiva/Eyelids/Orbit</b>	<b>Moderators:</b> Jill Wells, MD George Harocopos, MD
2:30 PM – 2:40 PM	Pterygoid-Myofibromatous Corneal Dystrophy in a Family with Germline PDGFRB Variant	Ralph Eagle, MD
2:40 PM – 2:50 PM	Detection of TTR Amyloid in the Conjunctiva Using a Novel Fluorescent Ocular Tracer	Tatyana Milman, MD
<b>2:50 PM – 3:15 PM</b>	<b>Refreshment Break &amp; Posters</b>	



3:15 PM –  
3:23 PM

### Questions for Poster Presenters

### Moderators:

Andrew Stacey, MD  
Amanda Maltry, MD

(1) OCT Applications in the Management of Retinoblastoma

Normila Barthelemy, MS

(2) Treatment of Choroidal Metastasis with Combined Photodynamic Therapy and Bevacizumab and Comparison with Photodynamic Therapy Alone

Aslan Aykut, MD

(3) Predictive Value of the International Classification of Diseases, 9th Revision Codes for Identifying Ocular Oncology Diagnoses

Kenny Wang, BS

3:23 PM –  
4:13 PM

### Free Papers - Section 4 (continued)

### Moderators:

Jill Wells, MD  
George Harocopus, MD

3:23 PM –  
3:33 PM

Brachytherapy-Boost Technique: Shaping Radiation Within the Orbit

Paul Finger, MD

3:33 PM –  
3:43 PM

Pembrolizumab, a PD-1 Immune Checkpoint Inhibitor, Monotherapy for Advanced Ocular Sebaceous Carcinoma

Hakan Demirci, MD

3:43 PM –  
3:53 PM

Ocular Histologic Findings in Abcc6 Knockout Rat Model of Pseudoxanthoma Elasticum

Anahita Sehgal, MD

3:53 PM –  
4:03 PM

Orbital Solitary Fibrous Tumor: The Utilization of STAT6 Immunohistochemistry

Chaow Charoenkijajorn, MD

4:03 PM –  
4:13 PM

Erdheim-Chester Disease with Orbital Involvement: 2 Cases Treated with BRAF and MEK Inhibitors

Sarinee Juntipwong, MD

4:13 PM –  
4:20 PM

### President's Closing Remarks

Matthew Wilson, MD  
President of AAOOP

### Accreditation Statement



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and American Association of Ophthalmic Oncologists and Pathologists. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### Credit Designation Statement

Medical Education Resources designates this live activity for a maximum of 6.5 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

